Clinical Research Directory
Browse clinical research sites, groups, and studies.
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
Sponsor: Rehab Werida
Summary
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).
Official title: Mitral Remodeling Index: A Novel Composite Measure the Effect of ARNI Alone Versus ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
180
Start Date
2025-12-25
Completion Date
2026-03-01
Last Updated
2026-01-30
Healthy Volunteers
Not specified
Conditions
Interventions
Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO]
Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet without concomitant SGLT2 inhibitor therapy.
Empagliflozin10Mg Tab
Combination Therapy Group: Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet in combination with an SGLT2 inhibitor (empagliflozin 10 mg daily).
Locations (1)
Madinah Cardiac Center
Madinah, Saudi Arabia